US 12,357,568 B2
Aerosol formulation for COPD
Sauro Bonelli, Parma (IT); Francesca Usberti, Parma (IT); and Enrico Zambelli, Parma (IT)
Assigned to Chiesi Farmaceutici S.p.A., Parma (IT)
Filed by CHIESI FARMACEUTICI S.p.A., Parma (IT)
Filed on Jan. 11, 2023, as Appl. No. 18/153,096.
Application 17/019,740 is a division of application No. 14/791,553, filed on Jul. 6, 2015, granted, now 10,806,701, issued on Oct. 20, 2020.
Application 18/153,096 is a continuation of application No. 17/019,740, filed on Sep. 14, 2020, granted, now 11,590,074.
Application 14/791,553 is a continuation of application No. 12/977,181, filed on Dec. 23, 2010, abandoned.
Claims priority of application No. 09015980 (EP), filed on Dec. 23, 2009.
Prior Publication US 2023/0157951 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/12 (2006.01); A61K 31/167 (2006.01); A61K 31/40 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61P 11/00 (2006.01); B65B 31/06 (2006.01); B65B 31/10 (2006.01)
CPC A61K 9/008 (2013.01) [A61K 31/167 (2013.01); A61K 31/40 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); B65B 31/06 (2013.01); B65B 31/10 (2013.01)] 62 Claims
 
1. A pharmaceutical composition for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide dissolved in HFA-134a and ethanol, wherein:
the composition comprises an amount of hydrochloric acid equivalent to 0.005 to 1.0 μg/μl of 1M hydrochloric acid;
the composition comprises glycopyrronium bromide in an amount of 0.015 to 0.04% w/w of the composition;
the composition comprises ethanol in an amount of 10 to 15% w/w of the composition;
the composition comprises HFA-134a in an amount of 85 to 90% w/w of the composition;
the composition comprises formoterol fumarate; and
the composition comprises beclometasone dipropionate.